- Home
- PAVM vs LITS Comparison
PAVM vs LITS Comparison
Compare PAVM & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAVM | LITS |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | United States |
| Employees | 41 | 4 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.1M | 44.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PAVM | LITS |
|---|---|---|
| Price | $6.42 | $1.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $65.00 | N/A |
| AVG Volume (30 Days) | 14.0K | ★ 299.1K |
| Earning Date | 05-15-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $603.94 | N/A |
| Revenue Next Year | $33.16 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.95 |
| 52 Week High | $28.44 | $3.03 |
Technical Indicators
Market Signals| Indicator | PAVM | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 31.54 | 58.28 |
| Support Level | $6.11 | $1.13 |
| Resistance Level | $10.98 | $1.65 |
| Average True Range (ATR) | 0.43 | 0.06 |
| MACD | -0.18 | 0.01 |
| Stochastic Oscillator | 11.93 | 92.11 |
Price Performance
Historical ComparisonAbout PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.